Class II alloantibody and mortality in simultaneous liver-kidney transplantation. - Wikidata - wikimedia - TriplyDB

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

http://www.wikidata.org/entity/Q35547071

about

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation HLA antibody detection with solid phase assays: great expectations or expectations too great?ABO-compatible liver allograft antibody-mediated rejection: an update.The role of donor-specific HLA alloantibodies in liver transplantation.Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss Codominant Role of Interferon-γ- and Interleukin-17-Producing T Cells During Rejection in Full Facial Transplant Recipients.Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice.Longterm renal allograft survival after sequential liver-kidney transplantation from a single living donor.Successful Simultaneous Liver-Kidney Transplantation in the Presence of Multiple High-Titered Class I and II Antidonor HLA Antibodies.Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts.Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients.Excessive immunosuppression as a potential cause of poor survival in simultaneous liver/kidney transplantation for hepatitis C.Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients.Transplantation: Alloantibodies in simultaneous liver-kidney transplantation.2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation.Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients.Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation.

P2860

Q26774993-BCAD9679-3002-434F-8F54-1AE33F33D58C Q26780271-E956F3B5-C162-448F-9AD6-C61A4D0E333F Q27015921-E1F4D5E8-A20F-4BEF-9335-379239321C68 Q33422561-A6CBD981-5D6A-428D-863F-01536F50558F Q35547041-B0FEC3F6-7AB5-4AC2-A0CE-FC3EEA13F615 Q36216606-BA63B94B-59D5-4D08-BA8D-65FCAD597A4D Q37164579-E623D4A3-B9B8-4243-BE7F-AA2133EB73C5 Q38757060-48B24909-49FD-4714-B2EA-2A71BBD77452 Q38793619-47BE692A-6963-43CF-9EF3-ACBB9CBAA05F Q39090125-EFB60C3A-4917-4AC5-8CB5-27A11022488C Q40429580-F2EC0065-9F38-473C-89D2-AF8C8CCFC542 Q42228443-BD52A8E9-50F2-45FB-AD20-9C18AFF10653 Q42233093-078A5142-725E-456A-8B42-55CAB591F34C Q44604343-2413A212-8F56-41C4-BEE4-6FB573754440 Q46039154-9A35286A-E9A2-4FA2-8E20-87ECAEE165B4 Q46360525-773AEBBB-7974-4372-A1FE-A8BC4083616C Q48202160-8FAB85C3-2F0B-4846-831A-AFED74ACD737 Q50266397-3EB0BFD8-A119-4028-958F-0B3EEC5C6C7D Q50895880-425026F2-E932-41A4-ACDA-A90540488CAA

P2860

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

http://www.wikidata.org/entity/Q35547071

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

@ast

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

@en

type

label

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

@ast

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

@en

prefLabel

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

@ast

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

@en

P1433

Q35547071-2DBCC3BC-2244-4981-98C9-8FD81D877448

P1476

Q35547071-19F51C32-C03D-4C1B-9184-4713116759BC

P2093

Q35547071-103223D5-64AA-4FF1-AA8F-26361F2A0DB9

Q35547071-10A6D72A-FFFC-48C3-B121-BBF6ACC82431

Q35547071-2EB07C03-E49C-4E63-9526-25350B40E8B0

Q35547071-358349C7-F617-48E4-85BC-5CC055DDE958

Q35547071-92E87433-C9C8-4E1F-BBF4-06742C7B91B1

Q35547071-C3D64325-5C1E-4608-BB6E-E2D381B07E03

Q35547071-C48D93B9-10B0-4230-899E-9113465952D1

Q35547071-C6055C38-A99A-4B42-86C8-DB3B6C645D99

Q35547071-D52C7EFE-37AC-4F83-8B53-35C35F632576

Q35547071-F23A95B5-516F-4F83-B3BD-8CA91DE52D2D

P2860

Q35547071-01AFADC8-B7A1-4AF5-85E4-8276FAB1FBAD

Q35547071-09118E71-B5C7-4F20-883B-8E70E526C38D

Q35547071-1680E4F9-5CC1-4859-8F57-99D48394DD10

Q35547071-24DC7A84-8634-4BC0-B3EB-E7A808DC1981

Q35547071-2D363616-64D0-4325-96D0-6EE82232F28E

Q35547071-3D344C88-0615-4F32-AAC9-2808F782FF3E

Q35547071-53D146DD-959B-437E-B29A-D90F098386E7

Q35547071-5D364551-D5A2-4FB7-A9BC-A74EEA4935F9

Q35547071-C55DCE5F-030E-414F-8ED0-77FCAC4CFFCD

Q35547071-DFEB9833-132B-486B-A5B1-E27D3918EC18

P304

Q35547071-5A4D0BDE-F95D-4787-B012-E5F6A2F9B476

P31

Q35547071-B3E0D566-C701-4476-94ED-D521F52CF0E9

P356

Q35547071-D7C76DD3-4EF1-40F7-BDCA-F30CD0762F34

P407

Q35547071-FD36B162-ED40-4E50-8462-BF3CB513BD80

P433

Q35547071-B7162AAB-8560-4988-AEA4-750503B7D3DE

P478

Q35547071-BC9FBC20-D24E-4B5F-B42E-0851E72949F2

P577

Q35547071-1FDBE170-EA5B-4981-8088-217201FC5355

P698

Q35547071-47275A4A-A886-4B73-8E04-429F09DD978D

P932

Q35547071-313CEB3A-F319-45C2-B604-6356E12892F7

P356

P1433

American Journal of Transplantation

P1476

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

@en

P2093

A D Kirk

http://www.w3.org/2001/XMLSchema#string

B M Susskind

http://www.w3.org/2001/XMLSchema#string

G B Klintmalm

http://www.w3.org/2001/XMLSchema#string

H M Gebel

http://www.w3.org/2001/XMLSchema#string

J D Marr

http://www.w3.org/2001/XMLSchema#string

J G O'Leary

http://www.w3.org/2001/XMLSchema#string

R A Bray

http://www.w3.org/2001/XMLSchema#string

R Ruiz

http://www.w3.org/2001/XMLSchema#string

S M Shiller

http://www.w3.org/2001/XMLSchema#string

X J Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy.

Bortezomib for acute antibody-mediated rejection in liver transplantation.

High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant.

The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody

Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants.

Combined liver-kidney transplants: allosensitization and recipient outcomes.

Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation.

Significance of a positive crossmatch on outcome in human liver transplantation.

Simultaneous HLA Class I and Class II antibodies screening with flow cytometry.

P304

954-960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJT.12147

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23433356

http://www.w3.org/2001/XMLSchema#string

P932

4412610

http://www.w3.org/2001/XMLSchema#string